GLP-1 Evidence

Druga

Tirzepatide: cad a léiríonn na trialacha

D'ardaigh tirzepatide na caillteanais meáchain meán is mó a taifeadadh riamh do dhruga i triala randamacha ar obezity. Is é freisin an ceann le na torthaí neamh-mhéadaithe is suimiúla.

Updated 4 min read 30 citations Evidence strength 5/5

Siopa cógaisíochta Gearmánach le feiceáil ón tsráid
muckelfloh · CC BY 3.0 · Wikimedia Commons

SURMOUNT-1: an méid éifeachta is mó sa réimse

Rinne SURMOUNT-1 daoine fásta le obezity agus gan diaibéiteas a randamú chuig tirzepatide 5, 10 nó 15 mg go seachtainiúil, nó placebo, ar feadh 72 seachtain [8]. Bhí an t-athrú meáchain meán ag an dáileog is airde thart ar −20.9%, le go raibh an dáileog 5 mg cheana thart ar −15% — ag ciallaíonn go raibh an dáileog tirzepatide is ísle comhoiriúnach go praiticiúil leis an toradh is fearr a bhí ag semaglutide. Chuaigh níos mó ná leath de na rannpháirtithe ag na dáileoga níos airde i gcion ar a laghad 20% de mheáchan an choirp.

Leanadh ar aghaidh leis an gclár sin a shíneadh an leanúnachas agus a thuairisciú ar chosc diaibéiteas in éineacht le laghdú meáchain leanúnach [5], rud a bhfuil tábhacht leis mar a bhogann sé an pointe deireadh ó uimhir ar scála go himeacht cliniciúil.

Éifeachtacht caillteanas meáchain

Cuireann an pionós diaibéiteas isteach anseo freisin

Rinne SURMOUNT-2 an prótacal céanna i ndaoine fásta le obezity agus diaibéiteas cineál 2 agus fuair sé thart ar 14.7% caillteanas meáchain meán ag an dáileog is airde [7]. Arís: éifeacht mhór, agus arís go bhfuil sé go mór níos lú ná i daonra neamh-diaibéitis. Cuireann an mheit-anailís a dhéanann comparáid idir na dá droga i diaibéiteas cineál 2 an t-ord reatha ar thalamh níos láidre [1][3].

Tirzepatide — athrú meáchain meán de réir triala agus daonra
TrialDaonraDáileogTréimhseAthrú meáchain meán
SURMOUNT-1 [8]Obezity, gan diaibéiteas15 mg72 seachtain≈ −20.9%
SURMOUNT-1 [8]Obezity, gan diaibéiteas5 mg72 seachtain≈ −15%
SURMOUNT-2 [7]Obezity + diaibéiteas cineál 215 mg72 seachtain≈ −14.7%
SURMOUNT-5 [10]Obezity, ceann ar cheann i gcoinne semaglutide≤15 mg72 seachtainSuperior do semaglutide

Ag buachan i gcoinne semaglutide go díreach

Bhí comparáidí indíreach agus comhoibrithe sa saol réalaíoch ag cur in iúl an treo seo le tamall [12], ach bhí an trial a shocraigh é ag comparáid na dá druga go ceann ar cheann ag dáileoga obezity sa daonra céanna, agus bhuaigh tirzepatide ar an meán caillteanas meáchain le margadh suntasach [10]. I diaibéiteas cineál 2, léirigh SURPASS-2 cheana superiority thar semaglutide 1 mg ar an dá phointe gliceamach agus meáchain [9].

Na torthaí nach bhfuil faoi mheáchan

Bhí dhá thrialacha tiomnaithe ag bogadh tirzepatide thar obezity mar chatagóir.

  • Apnoea codlata obstructive. I ndaoine fásta le OSA measartha go trom agus obezity, laghdaigh tirzepatide an t-innéacs apnoea-hypopnoea go suntasach i gcoinne placebo [6]. Is é seo an chéad chóireáil leighis le fianaise randamach i gcoinníoll a bhain le CPAP go praiticiúil.
  • Laige croí le frithghníomh eisiúna coimeádta. I HFpEF le obezity — cineál leighis le cúpla cóireáil éifeachtach — feabhsaigh tirzepatide torthaí i gcoinne placebo [4].
  • Imeachtaí croí agus soithigh. Rinne comparáid tiomnaithe i gcoinne dulaglutide torthaí croí agus soithigh i diaibéiteas cineál 2 [11], ag cur le mheit-anailís roimhe seo a fuair nach raibh aon chomhartha de dochar croí agus soithigh.

Léiríonn sé freisin sa treoir Eorpach ar ghalar ae steatóiseach in éineacht le semaglutide [2].

Ceisteanna coitianta

An é Mounjaro an rud céanna le Zepbound?
An móilín céanna, ainmneacha branda difriúla do na táscairí diaibéiteas agus otracht faoi seach.
An bhfuil tirzepatide níos fearr ná semaglutide, go simplí?
Ó thaobh meán-chaillteanas meáchain de i dtriail dhíreach otrachta, tá [10]. Maidir le gach rud eile — fulaingt do dhuine ar leith, costas, infhaighteacht, agus an chomhghalar ar leith atá á chóireáil agat — is aonair an freagra. Tá tacar sonraí toraidh cardashoithíoch níos mó ag semaglutide.
An é an comhpháirt GIP is cúis leis an gcaillteanas meáchain breise?
Is é an t-iarrthóir soiléir é, ach níl an mheicníocht réitithe i ndáiríre. Cruthaíonn blocáil GIP caillteanas meáchain freisin i roinnt samhlacha, ceann de na fadhbanna oscailte is aistí sa réimse.
An gcaithfidh mé 15 mg a bhaint amach?
Níl. Chruthaigh an dáileog 5 mg meán-chaillteanas timpeall 15% in SURMOUNT-1 [8], inchomparáide leis an toradh semaglutide is fearr. Déantar an dáileog a thiotrú in aghaidh fulaingthe.
Leaba bréagach i seomra ward leighis inmheánach do thrí dhuine
玄史生 · CC0 · Wikimedia Commons
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 12 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 31011meta-analysis (3)randomised trial (10)review (1)other (1)
11 foils, 2021–2025. Is measc é seo le trialacha agus sintéisí ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials Moiz A, Filion KB, Toutounchi H, et al. · Annals of internal medicine · 2025 · Systematic review DOIPubMed 39761578
  2. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  3. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary Diabetologia · 2024 · Clinical guideline DOIPubMed 38869512Full text
  4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  5. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  6. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  7. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation Ravussin E, Sanchez-Delgado G, Martin CK, et al. · Cell metabolism · 2025 · Randomised controlled trial DOIPubMed 40203836
  8. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  9. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial Kadowaki T, Kiyosue A, Shingaki T, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40031941
  10. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40318682
  11. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Packer M, Zile MR, Kramer CM, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 39555826
  12. Tirzepatide for Obesity Treatment and Diabetes Prevention Jastreboff AM, le Roux CW, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 39536238
  13. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Look M, Dunn JP, Kushner RF, et al. · Diabetes, obesity & metabolism · 2025 · Randomised controlled trial DOIPubMed 39996356Full text
  14. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial Aronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024 · Randomised controlled trial DOIPubMed 38078870Full text
  15. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial Zhao L, Cheng Z, Lu Y, et al. · JAMA · 2024 · Randomised controlled trial DOIPubMed 38819983Full text
  16. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity Malhotra A, Grunstein RR, Fietze I, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 38912654Full text
  17. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial Rosenstock J, Frías JP, Rodbard HW, et al. · JAMA · 2023 · Randomised controlled trial DOIPubMed 37786396Full text
  18. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet (London, England) · 2023 · Randomised controlled trial DOIPubMed 37385275
  19. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023 · Randomised controlled trial DOIPubMed 36857477Full text
  20. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial Dahl D, Onishi Y, Norwood P, et al. · JAMA · 2022 · Randomised controlled trial DOIPubMed 35133415Full text
  21. Tirzepatide Once Weekly for the Treatment of Obesity Jastreboff AM, Aronne LJ, Ahmad NN, et al. · The New England journal of medicine · 2022 · Randomised controlled trial DOIPubMed 35658024
  22. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  23. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025 · Clinical trial DOIPubMed 40353578
  26. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes Nicholls SJ, Pavo I, Bhatt DL, et al. · The New England journal of medicine · 2025 · Clinical trial DOIPubMed 41406444
  27. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Nauck MA, D'Alessio DA · Cardiovascular diabetology · 2022 · Review DOIPubMed 36050763Full text
  28. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Krüger N, Schneeweiss S, Fuse K, et al. · JAMA · 2025 · Journal article DOIPubMed 40886075Full text
  29. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text
  30. New Drug: Tirzepatide (Mounjaro(™)) Gettman L · The Senior care pharmacist · 2023 · Journal article DOIPubMed 36751934

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original